Recent Finacing
Recent Raise
Opsona Therapeutics is an innate-immunity drug developer developing OPN-305, a human IgG4 monoclonal antibody targeting TLR2, conducting multi-center placebo-controlled Phase II trials in high-risk renal transplant patients.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors